Raytest

Executive Summary

Elysia-Raytest, founded in 1985 and headquartered in Liège, Belgium, is a specialized provider of instrumentation, software, and systems for quality control and safe handling of radiopharmaceuticals. The company serves radiopharmacies, nuclear medicine departments, and radionuclide production facilities with a comprehensive portfolio including chromatography software, automated QC modules, radiation measurement systems, and radiation protection equipment. With over 35 years of experience, Raytest has established itself as a reliable partner in the nuclear medicine value chain, addressing the critical need for quality assurance in radiopharmaceutical preparation and administration. The growing adoption of theranostic pairs and targeted radionuclide therapies is driving demand for precise QC and handling solutions, positioning Raytest to benefit from the expansion of nuclear medicine. While the company operates in a niche but essential segment, its long-standing presence and specialized expertise provide a competitive moat. However, as a private entity with limited public disclosure, visibility into financial performance and growth initiatives is constrained. The company's conviction score reflects its stable market position tempered by the absence of recent public milestones or funding events.

Upcoming Catalysts (preview)

• TBDLaunch of Next-Generation Automated QC Module40% success
• TBDExpansion into North American Market via Distribution Partnership30% success
• TBDIncreased Demand from Theragnostic Radiopharmaceutical Adoption70% success